Parameters | N |
---|---|
N | 213 |
M/F | 106/107 |
Lifestyle | 5 (2.34) 2/3) |
Sulfonylureas, n (%) (M/F) | 42 (19.7) (18/24) |
Glyburide | 3 (7.1) (1/2) |
Glimepiride | 17 (40.5) (10/7) |
Gliclazide | 22 (52.4) (12/10) |
Biguanides, n (%) (M/F) | 153 (71.8) (71/82) |
Metformin | 153 (100) (71/82) |
Glinides, n (%) (M/F) | 32 (15.0) (17/15) |
Repaglinide | 32 (100) (17/15) |
α-glucosidase inhibitors, n (%) (M/F) | 33 (15.5) (14/19) |
Acarbose | 33 (100) (14/19) |
Thiazolidinediones, n (%) (M/F) | 28 (13.1) (15/13) |
Pioglitazone | 24 (85.7) (12/12) |
Rosiglitazone | 4 (14.3) (3/1) |
DPP-4 inhibitors, n (%) (M/F) | 33 (15.5) (17/16) |
Sitagliptin | 12 (36.4) (6/6) |
Vildagliptin | 10 (30.3) (6/4) |
Saxagliptin | 7 (21.2) (3/4) |
Linagliptin | 4 (12.1) (2/2) |
GLP-1 analogs, n (%) (M/F) | 15 (7.0) (8/7) |
Exenatide | 10 (66.7) (7/3) |
Liraglutide | 5 (33.3) (2/3) |